Klotho Neurosciences Regains Compliance with NASDAQ Listing Requirements

Strategic Insights -

Klotho Neurosciences, a gene and cell therapy company, has regained compliance with the minimum bid price and stockholders' equity threshold set by NASDAQ. The company's shares will remain listed and traded on the NASDAQ Stock Market after meeting the requirements. Klotho Neurosciences focuses on developing innovative cell and gene therapies for neurodegenerative and age-related disorders. The company has a pipeline of proprietary programs using DNA and RNA as therapeutics, as well as genomics-based diagnostic assays.

Key Takeaways:

  • Klotho Neurosciences has regained compliance with NASDAQ Listing Rule 5550(a)(2) on minimum bid price and Listing Rule 5550(b)(1) on stockholders' equity threshold.
  • The company will remain listed and traded on the NASDAQ Stock Market after meeting the requirements.
  • Klotho Neurosciences has a proprietary portfolio of cell and gene therapy programs using DNA and RNA as therapeutics, along with genomics-based diagnostic assays.
  • The company focuses on treating neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease.
  • A team of experienced individuals and advisors manages Klotho Neurosciences.

Statistics:

  • NASDAQ Listing Rule 5550(a)(2) minimum bid price: $1.00
  • NASDAQ Listing Rule 5550(b)(1) minimum stockholders' equity threshold: $2.5 million
  • Time period for ongoing compliance monitoring: 1 year
  • Number of diseases targeted by Klotho Neurosciences: 3 (ALS, Alzheimer's, and Parkinson's disease)

Sources:

  • "Klotho Neurosciences, Inc. Regains Compliance with NASDAQ Listing Requirements," PR Newswire, July 16, 2025.